Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of ...

As previously presented, gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) and gedatolisib + fulvestrant (“gedatolisib doublet”) ...
Targeted Oncology

Gedatolisib Combinations Improve PFS in PIK3CA Wild-Type Advanced Breast Cancer

PI3K/AKT/mTOR pathway blockade with pan-PI3K/mTORC1/2 inhibition produced substantial PFS gains in PIK3CA wild-type disease, addressing an unmet need after CDK4/6 plus endocrine resistance. Adding ...
EurekAlert!

ATOX1 promotes hepatocellular carcinoma carcinogenesis via activation of the c-Myb/PI3K/AKT signaling pathway

Antioxidant-1 may promote HCC carcinogenesis through the activation of the c-Myb/PI3K/AKT pathway and the inhibition of copper accumulation and oxidative stress. Despite advancements in diagnostic and ...
PharmiWeb

HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors

Second clinical candidate from HUTCHMED’s next-generation ATTC platform —— Leveraging synergy through simultaneous inhibition of PAM pathway and EGFR signaling — Hong Kong, Shanghai & Florham Park, NJ ...
ascopubs.org

PI3K/AKT/mTOR pathway and androgen receptor expression as potential therapeutic targets for triple-negative breast cancer.

Axillary recurrences in early breast cancer patients treated with sentinel node biopsy. Experience at the Instituto Nacional de Enfermedades Neoplasicas. Mifepristone (MIFE), a glucocorticoid receptor ...
ascopubs.org

Effect of PI3K inhibitor LY294002 combined with RAD001, a mTOR specificity inhibitor, on proliferation and apoptosis of triple-negative breast cancer cell lines MDA-MB-231 ...

Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple-negative breast cancer: A phase III study. This is an ASCO Meeting Abstract from the 2015 ASCO ...